Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bipolar Disorder01:30

Bipolar Disorder

938
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
938
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

9.3K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
9.3K
Bipolar Junction Transistor01:22

Bipolar Junction Transistor

1.5K
Bipolar Junction Transistors (BJTs) are essential elements in electronic circuits, playing a crucial role in the functionality of amplifiers, memories, and microprocessors. These transistors can be designed as NPN or PNP based on their doping patterns. They consist of three layers: the emitter, base, and collector. The configuration of these layers and their respective doping levels—with N-type or P-type impurities—define the transistor's type and its operational...
1.5K
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes02:16

Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes

17.0K
The present-day mitochondrial and chloroplast genomes have retained some of the characteristics of their ancestral prokaryotes and also have acquired new attributes during their evolution within eukaryotic cells. Like prokaryotic genomes, mitochondrial and chloroplast genomes neither bind with histone-like proteins nor show complex packaging into chromosome-like structures, as observed in eukaryotes. Unlike mitotic cell divisions observed in eukaryotic cells, mitochondria and chloroplasts...
17.0K
Intrinsically Disordered Proteins02:18

Intrinsically Disordered Proteins

19.6K
Intrinsically disordered proteins are a group of proteins that do not fold into specific three-dimensional structures. Their structural flexibility allows them to complement ordered proteins to perform functions that are inaccessible to rigid structures. They are more common in eukaryotes than prokaryotes and may either be exclusively intrinsically disordered or hybrid proteins, consisting of a mix of ordered and disordered regions. The absence of a rigid structure in these proteins can be...
19.6K
Export of Mitochondrial and Chloroplast Genes02:19

Export of Mitochondrial and Chloroplast Genes

4.2K
A eukaryotic cell can have up to three different types of genetic systems: nuclear, mitochondrial, and chloroplast. During evolution, organelles have exported many genes to the nucleus; this transfer is still ongoing in some plant species. Approximately 18% of the Arabidopsis thaliana nuclear genome is thought to be derived from the chloroplast’s cyanobacterial ancestor, and around 75% of the yeast genome derived from the mitochondria’s bacterial ancestor. This export has occurred...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency of Depressive Disorders in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Journal of Parkinson's disease·2022
Same author

Facilitating the Delivery of Cognitive Remediation in First-Episode Psychosis: Pilot Study of a Home-Delivered Web-Based Intervention.

The Journal of nervous and mental disease·2019
Same author

The renin-angiotensin system: a possible new target for depression.

BMC medicine·2017
Same author

Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials.

The Australian and New Zealand journal of psychiatry·2017
Same author

The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.

Clinical therapeutics·2017
Same author

A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena.

Clinical therapeutics·2017

Related Experiment Video

Updated: Feb 12, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.4K

Mitochondrial Agents for Bipolar Disorder.

Círia Pereira1,2, Victor Chavarria3, João Vian1,2

  • 1Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.

The International Journal of Neuropsychopharmacology
|March 30, 2018
PubMed
Summary

Mitochondrial agents show promise for treating bipolar disorder, offering new therapeutic avenues beyond current treatments. These agents are generally well-tolerated, suggesting a potential role in improving mood disorder recovery.

More Related Videos

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

2.0K
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K

Related Experiment Videos

Last Updated: Feb 12, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.4K
Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

2.0K
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Bipolar disorder is a chronic illness with incomplete recovery from existing treatments.
  • Pathophysiological understanding points to mitochondrial dysfunction as a therapeutic target.

Purpose of the Study:

  • To review the theoretical rationale and evidence for targeting mitochondria in bipolar disorder.
  • To explore preclinical and clinical data on mitochondrial agents for mood disorders.

Main Methods:

  • Conducted systematic literature searches (PubMed, ClinicalTrials.gov, ANZCTR) for mitochondrial agents in psychiatric disorders.
  • Included systematic reviews, RCTs, observational studies, case series, and animal studies.
  • Augmented search by manually reviewing references of key publications.

Main Results:

  • Mitochondrial agents present novel treatment possibilities for mood disorders.
  • Most agents reviewed were well-tolerated with generally benign side-effect profiles.

Conclusions:

  • Neuroinflammation, neurodegeneration, and mitochondrial function are key to understanding bipolar disorder.
  • Targeting these pathways offers potential therapeutic strategies.
  • Future research requires identifying new modulators and conducting robust clinical trials.